Gene-silencing compound is active in company’s Simplivir™ antiherpes and CY303 anti-inflammation products.
CytoGenix received notices of allowances for grant of patent applications covering the technology for expressing ssDNA in vivo from the Indian and European Community Patent Offices. These notices follow the previous notice of allowance for these applications from the Peoples Republic of China.
Filed in 1999 and 2000, these patents cover the company’s single-strand DNA expression system covered by a U.S. patent. It is used in the company’s Simplivir™ antiherpes and CY303 anti-inflammation products.
